Expansion Beyond Oncology:Despite the impressive overall achievements, the primary field of action for ADCs is still oncology, however, current research in this area is aimed at the development of ADCs for non-oncological applications, includ...
Pharma has a great opportunity ahead of it when it comes to conducting representative clinical trials. The industry’s application of mRNA techniques during the pandemic led to the fastest vaccine development in history. The processes used are now seeing
Astellas is taking a strategic approach to evolving its oncology portfolio, seeking to increase the number of patients who could benefit from its therapies. Initially, the company focused on specific cancer types that affected smaller groups of people, leveraging its deep scientific expertise in urolog...
Hiroyuki Okuzawa (hereinafter Okuzawa):Daiichi Sankyo has defined its 2025 Vision as becoming a ‘global pharma innovator with a competitive advantage in oncology’. To achieve this target and steadily shift to further growth to achieve the 2030 Vision of an ‘innovative global healthcare company co...
Is the Oncology Bubble Ready to Pop?Ramsey Baghdadi
(WHO) uses labels such as substandard, falsely labelled, falsified, and counterfeit to characterise medicines that are forged to appear authentic. Both generic and innovator medicines can be falsified, ranging from expensive products for oncology to inexpensive products such as analgesics. These ...
Until recently the application of artificial intelligence (AI) in precision oncology was confined to activities in drug development and had limited impact on the personalisation of therapy. Now, a number of approaches have been proposed for the personalisation of drug and cell therapies with AI appli...
Bromodomain and extra-terminal domain (BET) proteins are therapeutic targets in several cancers including the most common malignant adult brain tumor glioblastoma (GBM). Multiple small molecule inhibitors of BET proteins have been utilized in preclinical and clinical studies. Unfortunately, BET inhibitors...
the share price of biodelivery will rise. the business biodelivery science is a biopharmaceutical company which is involved in the development and commercialization of treatments for oncology supportive care and pain management. the company's products include onsolis which is a fentanyl buccal soluble fi...
The pharma giant is best known for blockbuster drugs such as Humira and Imbruvica, but analysts are also optimistic about the potential for Rinvoq and Skyrizi, which treat rheumatoid arthritis and plaque psoriasis. "AbbVie is developing new growth drivers to diversify away from Humira, still the ...